Consensus of Chinese experts on the pharmaceutical service for taxane anticancer drugs

Title: Consensus of Chinese experts on the pharmaceutical service for taxane anticancer drugs
Edition: Original
Classification: Experts consensus
Field: Treatment
Countries and regions: China
Guidelines users:
Evidence classification method: Relevant literatures on domestic and foreign guidelines, consensuses, and clinical studies were collected regularly to form a knowledge system for taxane anticancer drugs, and the GRADE method was used to score the collected evidence. At the same time, we coordinate the professional and clinicians to form an expert group, regularly exchange relevant clinical experience, and reach a consensus through the evaluation and optimization of the Delphi method.
Development unit: 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院
Registration time: 2022-05-23
Registration number: IPGRP-2022CN287
Purpose of the guideline: